Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
ADMA Biologics, Inc. (ADMA) · oqro.io/stocks/ADMA · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
Questions about ADMA Biologics, Inc. insider trading
Have ADMA Biologics, Inc. insiders bought shares recently?
No open-market purchase by an insider of ADMA Biologics, Inc. was filed in the last 90 days. The latest on record was on May 28, 2026.
How often do ADMA Biologics, Inc. insiders buy and sell shares?
Since 2013, ADMA Biologics, Inc. insiders reported 129 open-market purchases and 69 sales on Forms 4 and 5, with purchases in 12 different years, most recently 2026.
Who is selling ADMA Biologics, Inc. stock?
In the last 90 days, 2 insiders of ADMA Biologics, Inc. (ADMA) reported 5 open-market sales worth $2.19M in total on SEC Form 4. The largest seller by value was Adam S Grossman, with $2.05M. Many insider sales follow a plan set in advance or cover taxes on stock awards; the filing says what was sold, not the reason.
Do members of Congress trade ADMA?
No trade in ADMA Biologics, Inc. (ADMA) was disclosed by a member of Congress in the last 12 months.
Where does this data come from?
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
−19.5% (−$3.19) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
Adjusted close went from $16.36 on Nov 20, 2025 to $13.17 on Nov 20, 2026 (−19.5%). Disclosed in this range: 5 insider trades, 12 pre-arranged insider sales, 0 Congress trades, and 20 13F position changes for 4 quarters ending in it.
$5$10$15$20$25$13.17
DecJan 2026FebMarAprMayJunJulAugSepOctNov
13F holdings, by quarter end
Insider and Congress marks sit on the trade date stated in the filing; solid is a purchase, hollow a sale. A number means several trades too close to tell apart at this range: pick a shorter range or open it for the list. Fund 13F reports are quarter-end snapshots filed up to 45 days later, so they are shown under the chart across the quarter they describe, not on the price line. Congress amounts are official ranges; mark size uses the lower bound. Past moves are not a forecast.Show the 17 trades in this range as a list
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Biotechnology company based in Ramsey, New Jersey.
Last 12 months
−19.5%
S&P 500 +5.7% over the same dates
Market value
$2.92B
Close of Nov 20, 2026 × shares outstanding (per ADS where it applies)
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 18M shares sold short (8.1% of shares outstanding), −7.7% vs the previous count, 7.1 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
A Schedule 13G is filed by holders above 5% who say they will not try to influence the company. Index funds and large asset managers file most of them.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Insider buying and selling since 2013
Insiders of ADMA Biologics, Inc. reported 129 open-market purchases and 69 sales since 2013; purchases in 12 different years, most recently 2026.
Year
Bought
Sold
2026
$468K5×5 trades
$3.01M10×10 trades
2025
—
$13.5M27×27 trades
2024
—
$26.5M14×14 trades
2023
$580K2×2 trades
$10.7M6×6 trades
2022
$106K3×3 trades
—
2021
$580K5×5 trades
$4.25M9×9 trades
2020
$17.6M25×25 trades
—
2019
$16.3M7×7 trades
$21.8M1×1 trade
2018
$745K7×7 trades
—2×2 trades
2017
$13.6M5×5 trades
—
2016
$1.62M4×4 trades
—
2015
$459K33×33 trades
—
2014
$281K23×23 trades
—
2013
$7.08M10×10 trades
—
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Latest results: quarter ending Sep 30, 2026
Revenue
$141M
+5.1% vs the same quarter a year earlier
Free cash flow, last 12 months
$133M
This quarter $15.4M, a year earlier −$1.07M
Net debt
$71.3M
Debt $196M, cash $125M, at Sep 30, 2026
Net income, last 12 months
$182M
Operating profit covers interest 22.8x
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 4, 2026.
Latest annual report filed Feb 25, 2026, compared with the one filed Mar 18, 2025. Read the filing
New risk factors in the latest annual report (3 headings)
Our business may be adversely affected by a pandemic, epidemic, or outbreak of an unknown or emerging infections disease.
Issues in the development and use of AI may result in reputational harm and increased liability exposure.
There may be and have been changes in legal and regulatory requirements that may materially impact our results of operation.
No longer listed (1 heading from the year before)
Pandemics, or a resurgence of a pandemic, may adversely affect our business, financial condition, liquidity or results of operations.
Legal proceedings (Item 3)
We are and may become subject to certain legal proceedings and claims arising in connection with the normal course of our business. Neither the Company nor any of its subsidiaries are a party to any material pending legal proceedings, other than ordinary routine litigation incidental to our business.
Source: SEC EDGAR, Form 10-K filed Feb 25, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Where the revenue comes from
Latest quarter
The three months Jul 1, 2026 to Sep 30, 2026, compared with the same quarter a year earlier, from the quarterly report filed Nov 4, 2026. Quarterly reports are not audited. Read the filing
By business segment
ADMA BioManufacturing$141M100%
+5.1% on the same quarter a year earlier ($134M)
Plasma Collection Centers$25K0.0%
$0 the same quarter a year earlier
Total revenue$141M+5.1%
By region
United States$141M100%
+5.1% on the same quarter a year earlier ($134M)
International$275K0.2%
+12% on the same quarter a year earlier ($246K)
Total revenue$141M+5.1%
The full fiscal year ended Dec 31, 2025
Fiscal year Jan 1, 2025 to Dec 31, 2025, from the annual report filed Feb 25, 2026. Read the filing
By business segment
ADMA BioManufacturing$493M97%
+19% on the year before ($416M)
Plasma Collection Centers$17M3.3%
+62% on the year before ($10.5M)
Total revenue$510M+20%
By region
United States$504M99%
+23% on the year before ($410M)
The year in the managers' words
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 9,000 words.
From “Our Business”, in the company's words
ADMA Biologics, Inc. (the “Company,” “ADMA,” “we,” “us” or “our”) is a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. Our targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons. Through our ADMA BioManufacturing business segment, we currently have three products with U.S.
What the section covers (32 headings)
OVERVIEW
Our Business
Trends and Developments
Our Products
ASCENIV
BIVIGAM
Nabi-HB
RESULTS OF OPERATIONS
Critical Accounting Policies and Estimates
Revenue Deductions for Rebates and Chargebacks
Effective Tax Rate
- See Non-GAAP Financial Measures appearing at the end of this discussion
Revenues
Cost of Product Revenue and Gross Profit
Source: SEC EDGAR, Form 10-K filed Feb 25, 2026 and Form 10-Q filed Nov 4, 2026. Revenue lines are the figures the company tags in its filing; OQRO shows a split only when its lines add up to the reported total revenue. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
Since Nov 19, 2025, ADMA is down 17.4% and the index fund is up 4.1%: 22 points behind the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much ADMA moves
A usual day
±1.6%Half of the sessions moved less than this, half moved more.
Daily range (ATR 14)
4.7%How far the price usually travels in a session, the gap from the day before included. Wilder's 14-session average.
Largest one-day fall
−16.6%Mar 24, 2026
Largest one-day rise
+26.0%Nov 5, 2026
Deepest fall of the year
−62.7%From the close of Dec 11, 2025 to Jun 2, 2026.
Days of 5% or more
21Out of 252 sessions, in either direction.
Beta −0.0(1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 251 trading days (1 = in step with it).
Off-exchange trading: 37.0% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (18.5% on ATS, 18.5% with other brokers), close to its 26-week average of 37.0%. Weeks of Sep 21 to Oct 16, 2026.
Week of Apr 20ATSOther off-exchangeFull height = all shares tradedWeek of Oct 12
Largest ATS: INTELLIGENT CROSS LLC (13.4%), MS TRAJECTORY CROSS (ATS-1) (13.2%), UBS ATS (8.1%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
OQRO Intelligence
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Insiders. In the 12 months to Nov 19, 2026, insiders of ADMA Biologics, Inc. filed 5 open-market purchases (about $468K, in 4 filings, by 2 people) and 14 open-market sales (about $3.76M, in 8 filings, by 3 people). One Form 4 can list many transactions. In the 12 months before that, they filed 0 open-market purchases (about $0, in 0 filings) and 25 open-market sales (about $14.1M, in 14 filings). (ADMA Biologics, Inc. on OQRO)
Funds and stakes. Fund 13F filings recorded in the 12 months show 11 new or larger positions and 9 smaller or closed positions. A 13F is a snapshot of holdings at the end of a quarter. Rubric Capital Management LP now owns 5.5% of ADMA as a passive investor (filed Nov 16, 2026).
Contracts, lobbying and filings. FINRA short interest for ADMA on the settlement date of Oct 30, 2026 was 18,035,119 shares (-7.65% on the previous report), about 7.11 days of average volume. In 13F filings for the quarter ended Sep 30, 2026, the largest positions that grew: Bridgewater Associates (increased, 574,583 shares); the largest that shrank: Duquesne Family Office (reduced, 571,300 shares). A 13F is a quarter-end snapshot with no trade date.
Company reports, price and press. ADMA Biologics, Inc. filed a Form 8-K on Nov 4, 2026 (Item 2.02) that OQRO classes as: reported its results. ADMA Biologics, Inc. filed a Form 8-K on Aug 5, 2026 (Item 2.02) that OQRO classes as: reported its results.
Who holds it. 321 funds reported a stake in ADMA Biologics, Inc. in their 13F for Q2 2026. The largest by value: BlackRock, Inc. (18.6% of the value reported), STATE STREET CORP (8.3% of the value reported), VANGUARD CAPITAL MANAGEMENT LLC (4.9% of the value reported).
Things to keep in mind. These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why. A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade. Total compensation in a proxy statement counts stock and option awards at their grant-date value, not what was sold.
Facts used for this text
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
In the 12 months to Nov 19, 2026, insiders of ADMA Biologics, Inc. filed 5 open-market purchases (about $468K, in 4 filings, by 2 people) and 14 open-market sales (about $3.76M, in 8 filings, by 3 people). One Form 4 can list many transactions.
In the 12 months before that, they filed 0 open-market purchases (about $0, in 0 filings) and 25 open-market sales (about $14.1M, in 14 filings).
The largest purchase: Steve Elms, Director, about $110K, filed Mar 9, 2026.
The largest sale: Adam S Grossman, President and CEO, about $1.26M, filed Nov 6, 2026.
Funds and stakes
Fund 13F filings recorded in the 12 months show 11 new or larger positions and 9 smaller or closed positions. A 13F is a snapshot of holdings at the end of a quarter.
Rubric Capital Management LP now owns 5.5% of ADMA as a passive investor (filed Nov 16, 2026).
Contracts, lobbying and filings
FINRA short interest for ADMA on the settlement date of Oct 30, 2026 was 18,035,119 shares (-7.65% on the previous report), about 7.11 days of average volume.
In 13F filings for the quarter ended Sep 30, 2026, the largest positions that grew: Bridgewater Associates (increased, 574,583 shares); the largest that shrank: Duquesne Family Office (reduced, 571,300 shares). A 13F is a quarter-end snapshot with no trade date.
For fiscal 2025, the company's proxy statement reported total compensation of $10.2M for its principal executive officer, and an average of $2.87M for the other named executive officers.
Company reports, price and press
ADMA Biologics, Inc. filed a Form 8-K on Nov 4, 2026 (Item 2.02) that OQRO classes as: reported its results.
ADMA Biologics, Inc. filed a Form 8-K on Aug 5, 2026 (Item 2.02) that OQRO classes as: reported its results.
ADMA Biologics, Inc. filed a Form 8-K on Feb 25, 2026 (Items 2.02, 5.02) that OQRO classes as: changed a top executive or board member, and reported its results.
The company's own opening sentence of that report reads: "On February 20, 2026, Brad Tade notified the Company that he is retiring from his position as Chief Financial Officer and Treasurer of the Company effective at the close of business on February 25, 2026, following the filing of t..."
ADMA closed at $13.56 on Nov 18, 2026, the last session on or before the end of the period.
From Oct 19, 2026 to Nov 18, 2026, the close moved from $11.07 to $13.56, a change of +22.5%.
Who holds it
321 funds reported a stake in ADMA Biologics, Inc. in their 13F for Q2 2026. The largest by value: BlackRock, Inc. (18.6% of the value reported), STATE STREET CORP (8.3% of the value reported), VANGUARD CAPITAL MANAGEMENT LLC (4.9% of the value reported).
Things to keep in mind
These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why.
A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade.
Total compensation in a proxy statement counts stock and option awards at their grant-date value, not what was sold.
An 8-K item says what the company reported, not what it means for the share price.
Share price moves are listed as context only; the filing does not explain them and other news can move a price.
This describes public filings. It is not investment advice.
99 of 129 insider purchases since 2012 came within 30 days after a results announcement
From ADMA Biologics, Inc.'s own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know ADMA Biologics, Inc.'s policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.